BMY
Bristol-Myers Squibb Company NYSE Listed Jun 1, 1972$56.23
After hrs
$56.16
+0.00%
Mkt Cap $114.8B
52w Low $42.52
67.3% of range
52w High $62.89
50d MA $59.27
200d MA $52.15
P/E (TTM)
16.8x
EV/EBITDA
10.1x
P/B
6.4x
Debt/Equity
2.5x
ROE
38.2%
P/FCF
8.6x
RSI (14)
—
ATR (14)
—
Beta
0.27
50d MA
$59.27
200d MA
$52.15
Avg Volume
12.3M
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Route 206 & Province Line Road · Princeton, NJ 08543 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | 1.42 | 1.58 | +11.3% | 57.59 | +0.2% | +5.2% | +1.1% | -0.4% | -1.2% | -1.8% | — |
| Feb 5, 2026 | BMO | 1.23 | 1.26 | +2.4% | 57.62 | +2.2% | +3.3% | +7.6% | +5.5% | +5.6% | +4.0% | — |
| Oct 30, 2025 | BMO | 1.52 | 1.63 | +7.2% | 42.60 | +1.6% | +7.1% | +8.1% | +8.0% | +7.0% | +9.1% | — |
| Jul 31, 2025 | BMO | 1.09 | 1.46 | +33.9% | 45.98 | -3.9% | -5.8% | -3.8% | -1.3% | -0.3% | -2.5% | — |
| Apr 24, 2025 | BMO | 1.49 | 1.80 | +20.8% | 48.52 | -1.2% | +0.4% | -1.3% | -0.1% | +1.4% | +3.5% | — |
| Feb 6, 2025 | BMO | 1.47 | 1.67 | +13.6% | 59.71 | -3.9% | -3.8% | -4.8% | -7.0% | -6.3% | -6.0% | — |
| Oct 31, 2024 | BMO | 1.49 | 1.80 | +20.8% | 52.66 | +2.2% | +5.9% | +3.2% | +5.3% | +6.2% | +5.0% | — |
| Jul 26, 2024 | BMO | 1.62 | 2.07 | +27.8% | 45.27 | +6.6% | +11.4% | +8.2% | +8.3% | +5.1% | +6.4% | — |
| Apr 25, 2024 | BMO | -4.41 | -4.40 | +0.2% | 48.86 | -3.0% | -8.5% | -8.2% | -8.6% | -10.1% | -9.5% | — |
| Feb 2, 2024 | BMO | 1.52 | 1.70 | +11.8% | 48.67 | +1.2% | +0.1% | -1.4% | +1.2% | -0.1% | +0.1% | — |
| Oct 26, 2023 | BMO | 1.76 | 2.00 | +13.6% | 56.61 | -4.7% | -6.4% | -9.9% | -9.5% | -9.0% | -9.4% | — |
| Jul 27, 2023 | BMO | 1.99 | 1.75 | -12.1% | 63.41 | -3.8% | -4.2% | -3.2% | -1.9% | -3.0% | -2.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | BofA Securities | Maintains | Buy → Buy | — | $59.20 | $58.70 | -0.8% | +0.5% | -1.0% | -1.9% | -1.9% | -2.2% |
| Apr 8 | Guggenheim | Maintains | Buy → Buy | — | $57.67 | $58.01 | +0.6% | +2.7% | +3.1% | +1.6% | +0.7% | +0.7% |
| Apr 8 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $57.67 | $58.01 | +0.6% | +2.7% | +3.1% | +1.6% | +0.7% | +0.7% |
| Mar 17 | HSBC | Maintains | Hold → Hold | — | $59.71 | $60.13 | +0.7% | +0.0% | -0.6% | -2.7% | -3.7% | -4.5% |
| Feb 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $60.66 | $60.97 | +0.5% | +1.0% | +1.5% | +1.1% | +0.7% | +2.8% |
| Feb 6 | Citigroup | Maintains | Neutral → Neutral | — | $59.52 | $60.00 | +0.8% | +4.1% | +2.1% | +2.3% | +0.7% | +0.6% |
| Feb 6 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $59.52 | $60.00 | +0.8% | +4.1% | +2.1% | +2.3% | +0.7% | +0.6% |
| Feb 6 | Guggenheim | Maintains | Buy → Buy | — | $59.52 | $60.00 | +0.8% | +4.1% | +2.1% | +2.3% | +0.7% | +0.6% |
| Jan 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $55.56 | $55.01 | -1.0% | -1.7% | -2.3% | -0.9% | +0.6% | +0.8% |
| Jan 27 | Citigroup | Maintains | Neutral → Neutral | — | $54.60 | $54.56 | -0.1% | +1.8% | +0.0% | -0.6% | +0.8% | +2.4% |
| Jan 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $55.77 | $55.94 | +0.3% | +0.3% | +2.2% | +1.5% | -0.9% | -2.8% |
| Jan 9 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $55.90 | $55.72 | -0.3% | -0.1% | -0.2% | +0.0% | +2.0% | +1.3% |
| Jan 7 | Citigroup | Maintains | Neutral → Neutral | — | $54.42 | $55.24 | +1.5% | +4.2% | +2.7% | +2.6% | +2.5% | +2.8% |
| Jan 7 | UBS | Upgrade | Neutral → Buy | — | $54.42 | $55.24 | +1.5% | +4.2% | +2.7% | +2.6% | +2.5% | +2.8% |
| Dec 15 | BofA Securities | Upgrade | Neutral → Buy | — | $52.41 | $53.50 | +2.1% | +3.6% | +3.5% | +2.2% | +1.8% | +3.4% |
| Dec 12 | Guggenheim | Upgrade | Neutral → Buy | — | $51.20 | $52.27 | +2.1% | +2.4% | +6.0% | +5.9% | +4.6% | +4.2% |
| Dec 12 | Morgan Stanley | Maintains | Underweight → Underweight | — | $51.20 | $52.27 | +2.1% | +2.4% | +6.0% | +5.9% | +4.6% | +4.2% |
| Dec 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $50.65 | $50.79 | +0.3% | +1.1% | +1.1% | +3.5% | +7.2% | +7.1% |
| Dec 4 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $50.96 | $50.80 | -0.3% | +1.9% | +2.3% | +1.4% | -0.6% | +0.5% |
| Dec 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $49.18 | $48.95 | -0.5% | -1.9% | +3.6% | +5.6% | +6.0% | +5.1% |
| Nov 17 | Citigroup | Maintains | Neutral → Neutral | — | $46.65 | $46.52 | -0.3% | +0.3% | +0.9% | -1.8% | -1.5% | -0.9% |
| Aug 1 | Citigroup | Maintains | Neutral → Neutral | — | $43.31 | $43.61 | +0.7% | +2.1% | +4.8% | +5.9% | +3.5% | +4.7% |
| Jul 10 | Morgan Stanley | Maintains | Underweight → Underweight | — | $47.66 | $47.45 | -0.4% | +1.8% | -1.7% | -0.7% | -2.6% | -1.0% |
| Apr 28 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $47.90 | $48.31 | +0.9% | +1.2% | +2.8% | +4.8% | +3.6% | +5.6% |
| Apr 23 | Jefferies | Maintains | Buy → Buy | — | $49.82 | $47.63 | -4.4% | -2.6% | -2.3% | -3.9% | -2.7% | -1.2% |
| Apr 23 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $49.82 | $47.63 | -4.4% | -2.6% | -2.3% | -3.9% | -2.7% | -1.2% |
| Apr 11 | UBS | Maintains | Neutral → Neutral | — | $50.46 | $50.47 | +0.0% | +0.5% | +1.7% | -0.9% | -2.2% | -2.4% |
| Apr 8 | Goldman Sachs | Downgrade | Buy → Neutral | — | $55.19 | $55.17 | -0.0% | -3.8% | -2.6% | -8.6% | -8.1% | -7.0% |
| Feb 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $57.42 | $57.46 | +0.1% | -1.0% | -3.3% | -2.6% | -2.2% | -2.5% |
| Feb 4 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $59.95 | $58.87 | -1.8% | -1.4% | -0.4% | -4.2% | -5.2% | -7.4% |
| Jan 28 | Citigroup | Maintains | Neutral → Neutral | — | $60.62 | $60.28 | -0.6% | -3.1% | -2.6% | -2.4% | -2.8% | -1.1% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $57.14 | $56.98 | -0.3% | -0.6% | -2.3% | -3.1% | -2.5% | -2.2% |
| Dec 16 | Jefferies | Upgrade | Hold → Buy | — | $55.78 | $56.77 | +1.8% | +0.2% | +3.4% | +1.9% | +0.9% | +2.8% |
| Nov 12 | BMO Capital | Maintains | Market Perform → Market Perform | — | $59.82 | $59.82 | +0.0% | -1.3% | -2.4% | -2.2% | -6.0% | -5.0% |
| Nov 12 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $59.82 | $59.82 | +0.0% | -1.3% | -2.4% | -2.2% | -6.0% | -5.0% |
| Nov 12 | Morgan Stanley | Maintains | Underweight → Underweight | — | $59.82 | $59.82 | +0.0% | -1.3% | -2.4% | -2.2% | -6.0% | -5.0% |
| Nov 12 | Citigroup | Maintains | Neutral → Neutral | — | $59.82 | $59.82 | +0.0% | -1.3% | -2.4% | -2.2% | -6.0% | -5.0% |
| Nov 1 | BMO Capital | Maintains | Market Perform → Market Perform | — | $55.77 | $55.88 | +0.2% | -2.6% | -0.6% | +0.3% | -0.9% | -1.9% |
| Oct 25 | Citigroup | Downgrade | Buy → Neutral | — | $52.92 | $52.68 | -0.5% | -1.9% | -0.5% | -0.8% | -0.5% | +5.4% |
| Oct 18 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $53.18 | $53.26 | +0.2% | +0.1% | -2.0% | -0.8% | -0.2% | -0.5% |
| Oct 9 | UBS | Maintains | Neutral → Neutral | — | $52.48 | $52.25 | -0.4% | +0.6% | -0.2% | -0.5% | +0.4% | +0.5% |
| Oct 7 | TD Cowen | Maintains | Hold → Hold | — | $53.96 | $54.00 | +0.1% | -1.0% | -2.7% | -2.1% | -2.9% | -3.3% |
| Oct 7 | Barclays | Maintains | Underweight → Underweight | — | $53.96 | $54.00 | +0.1% | -1.0% | -2.7% | -2.1% | -2.9% | -3.3% |
| Sep 27 | BMO Capital | Maintains | Market Perform → Market Perform | — | $50.12 | $51.54 | +2.8% | +1.6% | +3.2% | +5.5% | +7.3% | +8.1% |
| Sep 23 | BMO Capital | Maintains | Market Perform → Market Perform | — | $49.41 | $49.56 | +0.3% | +1.2% | +3.1% | +1.1% | +1.4% | +3.0% |
| Sep 16 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $49.13 | $49.50 | +0.8% | +1.8% | +0.7% | +1.2% | -0.2% | +0.6% |
| Aug 28 | Jefferies | Maintains | Hold → Hold | — | $48.12 | $48.12 | +0.0% | +2.0% | +3.3% | +3.8% | +5.0% | +3.8% |
| Aug 22 | Barclays | Maintains | Underweight → Underweight | — | $48.44 | $48.57 | +0.3% | -1.7% | -0.7% | -0.4% | -0.7% | +1.3% |
| Aug 12 | TD Cowen | Maintains | Hold → Hold | — | $46.72 | $46.77 | +0.1% | +0.7% | +5.0% | +3.6% | +5.1% | +5.7% |
| Jul 29 | Barclays | Downgrade | Equal Weight → Underweight | — | $50.45 | $49.92 | -1.1% | -2.9% | -2.8% | -5.7% | -4.5% | -3.3% |
No insider trades available.
8-K
Bristol-Myers Squibb Company -- 8-K Filing
May 8
8-K · 7.01
! Medium
BRISTOL MYERS SQUIBB CO -- 8-K 7.01: Regulation FD Disclosure
Bristol Myers Squibb disclosed Q1 2026 financial results and operational initiatives via investor presentation, providing transparency on company performance and strategic direction to shareholders.
Apr 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Colgate-Palmolive's CEO is departing the board to lead Kraft Heinz, signaling leadership transition uncertainty at CL while potentially strengthening KHC's management team.
Mar 12
8-K · 5.02
!!! Very High
Protagenic Therapeutics, Inc.\new -- 8-K 5.02: Executive Change
Protagenic Therapeutics appoints Nichols as President, signaling potential leadership restructuring that could affect company strategy and investor confidence in the biotech firm's direction.
Mar 3
8-K · 5.02
!!! Very High
Atrium Therapeutics, Inc. -- 8-K 5.02: Executive Change
Atrium Therapeutics appointed four new directors following its distribution from Bristol Myers Squibb, signaling completion of the planned spinoff and establishment of independent board governance.
Feb 27
8-K · 7.01
! Medium
Bristol-Myers Squibb Co. -- 8-K 7.01: Regulation FD Disclosure
Bristol-Myers Squibb disclosed financial and operating initiatives via a presentation posted ahead of its Q4 2025 earnings call, providing investors with strategic information concurrent with results announcement.
Feb 5
Data updated apr 24, 2026 10:16pm
· Source: massive.com